Movement Alert｜Vaxcyte, Inc. Falls 5.08% in Regular Trading, Shares Pull Back After Vaccine Trial Gains

Market Focus10-14 03:21

On October 14, Vaxcyte, Inc. fell 5.08% in Regular Trading, trading at $67.065 per share, with turnover of $88.5663 million.

The clearest recent catalyst remains the company’s positive topline Phase 3 OPUS-1 data for pneumococcal conjugate vaccine candidate VAX-31, but the latest move appears to reflect a pullback after that upside catalyst had already been priced in.

Earlier this month, Vaxcyte, Inc. said VAX-31 met all pre-specified primary endpoints across studied age groups, with safety and tolerability comparable to Prevnar 20 and or Capvaxive. The company said these data support its planned BLA submission in the first half of 2028, while a subsequent analyst action raised the price target to $122 from $110 and maintained a Buy rating. Those developments had already driven a sharp rally in the shares, making the current decline more consistent with post-news profit-taking than with a new negative fundamental update.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment